US Patent Issued to Leap Therapeutics on June 3 for "Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody" (Massachusetts Inventors)

ALEXANDRIA, Va., June 4 -- United States Patent no. 12,319,730, issued on June 3, was assigned to Leap Therapeutics Inc. (Cambridge, Mass.).

"Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody" was invented by Michael H. Kagey (Arlington, Mass.) and Cynthia A. Sirard (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a cons...